An investigation for investors in Prothena Corporation plc (NASDAQ: PRTA) shares over potential securities laws violations by Prothena Corporation plc was announced.
San Diego, CA -- (SBWIRE) -- 05/08/2018 -- Prothena Corporation plc is under investigation over potential securities laws violations in connection with certain financial statements made by Prothena Corporation plc.
Investors who purchased shares of Prothena Corporation plc (NASDAQ: PRTA), have certain options and should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 - 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Prothena Corporation plc (NASDAQ: PRTA) concerning whether a series of statements by Prothena Corporation plc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
Ireland based Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases in the neuroscience and orphan categories. On April 23, 2018, Prothena Corporation plc announced that it "is discontinuing development of NEOD001, an investigational antibody that was being evaluated for the treatment of AL amyloidosis."
Prothena Corporation plc advised investors that "[b]ased on the results from the Phase 2b PRONTO study, which did not meet its primary or secondary endpoints, the Company asked the independent data monitoring committee (DMC) of the Phase 3 VITAL study to review a futility analysis of the ongoing VITAL study. The DMC recommended discontinuation of the VITAL study for futility." Shares of Prothena Corporation plc (NASDAQ: PRTA) declined to as low as $10.43 per share on April 25, 2018.
On April 30, 2018, shares of Prothena Corporation plc (NASDAQ: PRTA) closed at $12.00 per share.
Those who purchased shares of Prothena Corporation plc (NASDAQ: PRTA) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego
For more information on this press release visit:
Media Relations Contact
Email: Click to Email Michael Daniels